Publication | Open Access

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Drug TargetingHer2-targeted TherapyMedicineImmunologyImmunoeditingImmune Checkpoint InhibitorPrimary Models RefractoryTumor TargetingCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentCancer Research